IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 381 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,812,099 | +30201550.0% | 39,948 | +7325.3% | 0.01% | +800.0% |
| Q2 2023 | $6 | -98.7% | 538 | -95.3% | 0.00% | -75.0% |
| Q4 2022 | $459 | -99.9% | 11,522 | -0.1% | 0.00% | 0.0% |
| Q3 2022 | $516,000 | +12.4% | 11,539 | -1.2% | 0.00% | 0.0% |
| Q2 2022 | $459,000 | -9.3% | 11,684 | -0.6% | 0.00% | 0.0% |
| Q1 2022 | $506,000 | +36.8% | 11,755 | 0.0% | 0.00% | +33.3% |
| Q4 2021 | $370,000 | +2.8% | 11,755 | -0.6% | 0.00% | +50.0% |
| Q3 2021 | $360,000 | -39.0% | 11,830 | -24.1% | 0.00% | -50.0% |
| Q2 2021 | $590,000 | -11.9% | 15,591 | -0.7% | 0.00% | 0.0% |
| Q1 2021 | $670,000 | -32.4% | 15,696 | -2.2% | 0.00% | -33.3% |
| Q4 2020 | $991,000 | +26.7% | 16,048 | -2.8% | 0.01% | 0.0% |
| Q3 2020 | $782,000 | -22.3% | 16,514 | -0.4% | 0.01% | -25.0% |
| Q2 2020 | $1,006,000 | +6.3% | 16,576 | +1.8% | 0.01% | -11.1% |
| Q1 2020 | $946,000 | 0.0% | 16,279 | +2.5% | 0.01% | +28.6% |
| Q4 2019 | $946,000 | +12.1% | 15,879 | +1.3% | 0.01% | 0.0% |
| Q3 2019 | $844,000 | -19.7% | 15,674 | +0.5% | 0.01% | -12.5% |
| Q2 2019 | $1,051,000 | -20.4% | 15,590 | +1.1% | 0.01% | -27.3% |
| Q1 2019 | $1,320,000 | +56.8% | 15,420 | -0.0% | 0.01% | +57.1% |
| Q4 2018 | $842,000 | +9.2% | 15,424 | -2.3% | 0.01% | +16.7% |
| Q3 2018 | $771,000 | +9.5% | 15,792 | -1.0% | 0.01% | +20.0% |
| Q2 2018 | $704,000 | -3.7% | 15,956 | +0.1% | 0.01% | 0.0% |
| Q1 2018 | $731,000 | -14.7% | 15,948 | -0.8% | 0.01% | -16.7% |
| Q4 2017 | $857,000 | -9.2% | 16,069 | -0.7% | 0.01% | -14.3% |
| Q3 2017 | $944,000 | -2.0% | 16,181 | +0.1% | 0.01% | 0.0% |
| Q2 2017 | $963,000 | +22.4% | 16,171 | -2.3% | 0.01% | +16.7% |
| Q1 2017 | $787,000 | -0.9% | 16,544 | +0.2% | 0.01% | 0.0% |
| Q4 2016 | $794,000 | +87.3% | 16,505 | +33.3% | 0.01% | +50.0% |
| Q3 2016 | $424,000 | -3.0% | 12,383 | +3.0% | 0.00% | 0.0% |
| Q2 2016 | $437,000 | -15.6% | 12,028 | -1.4% | 0.00% | -20.0% |
| Q1 2016 | $518,000 | -23.6% | 12,193 | +2.2% | 0.01% | -28.6% |
| Q4 2015 | $678,000 | – | 11,926 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |